Rhenman & Partners Asset Management AB Cuts Holdings in Natera, Inc. (NASDAQ:NTRA)

Rhenman & Partners Asset Management AB lowered its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 46.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,410 shares of the medical research company's stock after selling 107,590 shares during the period. Natera comprises about 2.0% of Rhenman & Partners Asset Management AB's portfolio, making the stock its 17th largest position. Rhenman & Partners Asset Management AB owned about 0.09% of Natera worth $19,536,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Blue Trust Inc. grew its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc boosted its holdings in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after purchasing an additional 166 shares during the period. EverSource Wealth Advisors LLC grew its position in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after buying an additional 261 shares in the last quarter. Principal Securities Inc. raised its holdings in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after acquiring an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after acquiring an additional 332 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on NTRA shares. BTIG Research reaffirmed a "buy" rating on shares of Natera in a research note on Friday, February 28th. Robert W. Baird boosted their price objective on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Royal Bank of Canada began coverage on shares of Natera in a research report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price on the stock. Guggenheim boosted their price target on shares of Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. Finally, Piper Sandler lifted their price objective on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and a consensus target price of $175.76.

Insiders Place Their Bets

In other news, CFO Michael Burkes Brophy sold 2,562 shares of Natera stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42. Following the transaction, the chief financial officer now directly owns 75,557 shares of the company's stock, valued at $10,457,844.37. The trade was a 3.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 24,861 shares of Natera stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the transaction, the insider now directly owns 140,684 shares in the company, valued at $23,208,639.48. This represents a 15.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 325,922 shares of company stock valued at $51,603,664. 7.60% of the stock is owned by insiders.

Natera Stock Down 7.5 %

Shares of NASDAQ NTRA traded down $11.36 on Thursday, reaching $140.61. 872,544 shares of the company's stock traded hands, compared to its average volume of 1,750,703. The business's 50 day simple moving average is $153.85 and its two-hundred day simple moving average is $151.75. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00. The company has a market cap of $19.01 billion, a price-to-earnings ratio of -80.01 and a beta of 1.80. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. As a group, equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.